National Cancer Institute (NCI)
NCI Public Inquiries Office
Building, 31, Room 10A03<br>31 Center Drive, MSC 2
Bethesda
Maryland
20892-2580
United States
Tel: 301-435-3848
Website: http://www.nci.nih.gov/
819 articles about National Cancer Institute (NCI)
-
Abilita Bio Awarded NCI Phase-I SBIR Grant To Develop Therapeutic Antibodies Targeting Metastatic Breast Cancer
9/20/2016
-
BioMarker Strategies Awarded Phase I NCI Contract To Develop Novel Predictive Test For Response To Immunotherapies For Patients With Non-Small Cell Lung Cancer
9/19/2016
-
Lumicell Awarded Direct Phase II SBIR Grant From The NCI To Conduct Multi-Center Pivotal Study
8/9/2016
-
Cellectar Biosciences Announces $2 Million NCI SBIR Contract For A Phase II Clinical Study
8/3/2016
-
Advanced Accelerator Applications Announces Clinical Trial Agreement With NCI For Study Of Lutathera In Patients With Inoperable Pheochromocytoma And Paraganglioma
8/2/2016
-
President's Cancer Moonshot Initiative Fosters Breakthrough Collaboration Between The Colon Cancer Alliance, Smart Patients, And The Colon Cancer Alliance
6/30/2016
-
Cellectar Biosciences Announces Results Of NCI-Sponsored Study Of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer
6/23/2016
-
Kite Pharma Expands Development Of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers In Partnership With The NCI
6/20/2016
-
Pharmaron LLC Joins The NCI’s Chemical Biology Consortium To Fight Against Cancer
6/14/2016
-
ASCO2016: Kite Pharma/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions In Advanced Non-Hodgkin Lymphoma
6/6/2016
-
Former NCI And NIH Director Dr. Harold Varmus Joins The International Biomedical Research Alliance Board
6/2/2016
-
Kite Pharma Cancer Therapy Responses in Solid Tumors Continued in Small Trial, NCI Review Halts Patient Enrollment
4/18/2016
-
Altor BioScience Corporation Partners With The NCI To Further Develop Altor’s ALT-803 And ALT-801 Cancer Immunotherapeutics
4/11/2016
-
NantBioscience Partner With The NantKwest To Further Develop Recombinant NK Cells And Monoclonal Antibodies As Monotherapies And Combination Cancer Immunotherapies
4/5/2016
-
RareCyte Announces CRADA With NCI In Immunology/Oncology
3/14/2016
-
SRI International Receives $19.8 Million NCI Contract For PREVENT Cancer Program
3/11/2016
-
PDS Biotechnology Corporation Signs Agreement With NCI To Form Phase II Clinical Collaboration For Novel Cancer Immunotherapies Based On PDS' Versamune Platform Technology
2/9/2016
-
Solaranrx Signs Research Agreement With The NCI To Advance Metastatic Melanoma Theranostic
1/7/2016
-
BeyondSpring Data Demonstrating Activity Of Plinabulin In Kras-Mutant Tumors Presented At AACR-NCI-EORTC International Conference 2015
11/17/2015
-
Tesaro Announces Data Presentations For Niraparib At The 2015 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
11/9/2015